Nikolay Novitski/LinkedIn
May 5, 2026, 16:28
Nikolay Novitski: A New Era in Cardiovascular Prevention
Nikolay Novitski, Deputy chief physician, Associate professor Kaluga university, Board member Russian HF society, shared a post on X:
”Lipoprotein(a), or Lp(a), is an important cardiovascular risk factor that is largely unaffected by lifestyle changes or statin therapy.
Emerging therapies include:
- Pela (ASO) – approximately an 80 percent reduction (expected in 2026)
- Olpa (siRNA) – approximately a 71 to 101 percent reduction (expected in 2026)
- Lepo (siRNA) – approximately a 94 percent reduction, with effects lasting up to 1.5 years after a single injection
- Muva (oral) – approximately an 86 percent reduction in Lp(a)
Important note:
- Very low Lp(a) levels may be associated with an increased risk of type 2 diabetes.”
Stay updated with Hemostasis Today.
-
May 11, 2026, 16:52Luke McLaughlin: Raising Awareness on Haemophilia Issues at ENIL Lead On
-
May 11, 2026, 16:49Jeff Sternlicht: Normal LDL Does Not Always Mean Low Risk
-
May 11, 2026, 16:42Archil Jaliashvili: From Managing Blood to Managing Oxygen Metabolism
-
May 11, 2026, 16:42Heghine Khachatryan: Celebrating One Hundred Years of von Willebrand Disease with EHC
-
May 11, 2026, 16:34Jane Hankins: Excited to Have Been a Part of the Faculty of ASH CRTI LA
-
May 11, 2026, 16:28Conan McIlwrath at the Rare Bleeding Disorders Conference Representing The Haemophilia Society as Chair
-
May 11, 2026, 16:24Anna A. Avagyan: Presenting Armenia’s Experience at SIOP Europe 2026
-
May 11, 2026, 16:18Mohamed Elkhider: Raising Awareness on Aortic Dissection
-
May 11, 2026, 16:11David McIntosh: A Pensioner’s Reflections on Blood Donation